Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 110 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Antibiotic Resistant Infection Clear all
Completed No phase listed Observational

Antibiotic Resistant Community-Acquired E. Coli

NCT00298103
View directory record Official record
Conditions
E Coli Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection

NCT00822692
View directory record Official record
Conditions
Abscess, Methicillin-Resistant Staphylococcus Aureus Infection
Interventions
Trim/ Sulfa DS, placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Sep 30, 2026, 7:46 AM EDT
Recruiting Phase 2 Interventional

Further MT for Antibiotic-Resistant Bacterial Colonization

NCT05835206
View directory record Official record
Conditions
Intestinal Multi-drug Resistant Organism Colonization
Interventions
Microbiome Therapeutic, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Phase 2 Interventional

Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation

NCT00396578
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Respiratory Infection, Tracheobronchitis
Interventions
aerosolized vancomycin or gentamicin
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2006 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Early Phase 1 Interventional

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

NCT01878643
View directory record Official record
Conditions
Respiratory Infection, Bacterial Resistance, Respiratory Failure
Interventions
vancomycin or gentamicin, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 30, 2026, 7:46 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance

NCT01511107
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Amoxicillin-Clavulanate, 10 days, Amoxicillin-Clavulanate, 5 days
Drug
Lead sponsor
Alejandro Hoberman
Other
Eligibility
6 Months to 23 Months
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Bardstown, Kentucky • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso

NCT03187834
View directory record Official record
Conditions
Child Development
Interventions
Azithromycin, Amoxicillin, Cotrimoxazole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 59 Months
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 30, 2026, 7:46 AM EDT
Terminated Phase 3 Interventional Results available

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

NCT04160468
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
Exebacase, Placebo
Drug
Lead sponsor
ContraFect
Industry
Eligibility
12 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
55
States / cities
Birmingham, Alabama • Orange, California • Sacramento, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Not applicable Interventional

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

NCT00000796
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Cycloserine, Ethionamide, Capreomycin sulfate, Aminosalicylic acid, Streptomycin sulfate, Ethambutol hydrochloride, Amikacin sulfate, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin, Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
21
States / cities
Chicago, Illinois • Detroit, Michigan • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 30, 2026, 7:46 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

NCT04597242
View directory record Official record
Conditions
MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
Interventions
Exebacase
Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years and older
U.S. locations
2
States / cities
Butte, Montana • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Phase 3 Interventional

New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

NCT00035854
View directory record Official record
Conditions
Bacterial Infections
Interventions
Zyvox® / Linezolid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Up to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
21
States / cities
Long Beach, California • Los Angeles, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2009 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections

NCT04763759
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
TRL1068, a human monoclonal antibody
Drug
Lead sponsor
Trellis Bioscience LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 30, 2026, 7:46 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection

NCT06621251
View directory record Official record
Conditions
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Interventions
TRL1068 (calpurbatug), a human monoclonal antibody, DAIR
Drug · Procedure
Lead sponsor
Trellis Bioscience LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Gilbert, Arizona • Los Angeles, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 30, 2026, 7:46 AM EDT
Completed No phase listed Observational

Benefits of Universal Glove and Gowning

NCT01318213
View directory record Official record
Conditions
MRSA, VRE
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
19,856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Phase 4 Interventional Results available

Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization

NCT03118232
View directory record Official record
Conditions
Hospitalization, Infection
Interventions
Chlorhexidine gluconate (CHG), Iodophor (10% povidone-iodine)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
13,952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
28
States / cities
Anaheim, California • Bellflower, California • Capistrano Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 30, 2026, 7:46 AM EDT
Enrolling by invitation No phase listed Observational

Surveillance of Healthcare-associated Infections & Antimicrobial Resistance

NCT05734391
View directory record Official record
Conditions
Antimicrobial Resistance
Interventions
Routine Infection control
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Sep 30, 2026, 7:46 AM EDT
Withdrawn Not applicable Interventional

Antibiotic Therapy After Incision and Drainage for Abscess

NCT00900510
View directory record Official record
Conditions
Abscess
Interventions
Incision and drainage, Trimethoprim/Sulfamethoxazole (Bactrim), Placebo
Procedure · Drug
Lead sponsor
Wake Forest University
Other
Eligibility
6 Months to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 30, 2026, 7:46 AM EDT
Active, not recruiting No phase listed Observational

Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation

NCT07226557
View directory record Official record
Conditions
Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection, Antimicrobial Drug Resistance
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Phase 4 Interventional

IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

NCT02660346
View directory record Official record
Conditions
Bacteremia
Interventions
Daptomycin, Vancomycin, Ceftaroline
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Sep 30, 2026, 7:46 AM EDT
Completed No phase listed Observational

Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs

NCT03346603
View directory record Official record
Conditions
Urinary Tract Infections, Urosepsis
Interventions
urine culture and susceptibility testing
Other
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
18 Years and older
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Not applicable Interventional

Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial

NCT00100386
View directory record Official record
Conditions
Bacterial Diseases
Interventions
Intensive Control Strategy, Standard Control Strategy
Procedure · Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Sep 30, 2026, 7:46 AM EDT
Completed No phase listed Observational

Towards Reducing Resistance and Hematological Toxicity of Linezolid

NCT00177723
View directory record Official record
Conditions
Infection, Adverse Effects
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Sep 30, 2026, 7:46 AM EDT
Terminated Phase 3 Interventional

Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU

NCT00307099
View directory record Official record
Conditions
Bacterial Infection
Interventions
Meropenem, Standard antibiotic therapy
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Newark, Delaware • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2013 · Synced Sep 30, 2026, 7:46 AM EDT
Completed Phase 4 Interventional

Staph Intervention for Effective Local Defense

NCT06210594
View directory record Official record
Conditions
Staphylococcus Aureus Infection
Interventions
Mupirocin + Nozin + chlorhexidine gluconate, Education + Household supplies
Combination Product · Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Sep 30, 2026, 7:46 AM EDT